Janet L. Anderl

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

Shirin Arastu‐Kapur, Janet L. Anderl, Marianne Kraus et al. · Clinical Cancer Research · 2011 · 409 citations

Medicine, Pharmacology, Pharmacotherapy +15

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2<i>S</i>,3<i>R</i>)-<i>N</i>-((<i>S</i>)-3-(Cyclopent-1-en-1-yl)-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((<i>S</i>)-2-(2-morpholinoacetamido)propanamido)propenamide)

Henry W. B. Johnson, Eric Lowe, Janet L. Anderl et al. · Journal of Medicinal Chemistry · 2018 · 100 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

James R. Berenson, Alan Cartmell, Alberto Bessudo et al. · Blood · 2016 · 94 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Immunoproteasome functions explained by divergence in cleavage specificity and regulation

Michael B. Winter, Florencia La Greca, Shirin Arastu‐Kapur et al. · eLife · 2017 · 81 citations · Full text

Life Sciences, Biochemistry, Immunology +17

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines

Denise Niewerth, Gertjan J.L. Kaspers, Yehuda G. Assaraf et al. · Journal of Hematology & Oncology · 2014 · 70 citations · Full text

Medicine, Immunology, Oncology +13